Abstract: AIM: To design and synthesize a new analogue of salidroside-tyrosol galactoside, observe its protective effects on focal cerebral and cardiac ischemia/reperfusion (I/R) injuries and compare its protective effects with those of salidroside. METHODS: Using the model of middle cerebral artery occlusion (MCAO), we evaluated functions of cerebral protection by neurological behavior score (NBS) and TTC staining. In the model of myocardial I/R, left ventricular systolic pressure (LVSP) and maximal first derivative of developed pressure (±dP/dtmax) were monitored throughout the experiments. Serum creatine kinase (CK) and malondialdehyde (MDA) were detected at the end of reperfusion for evaluation of cardiac protection. RESULTS: Tyrosol galactoside and salidroside significantly improved NBS and reduced cerebral infarction volume with no statistical difference. In myocardial protection, tyrosol galactoside significantly increased LVSP and (±dP/dtmax) and decreased activities of CK. Level of MDAI and its protective effect was stronger than that of salidroside. CONCLUSION: Tyrosol galactoside and salidroside both have obvious protective effects on heart and brain. However, compared with salidroside, tyrosol galactoside has stronger effects on myocardial protection.